Literature DB >> 24297598

Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase.

Elsa Iannicelli1, Marco Di Pietropaolo, Massimo Marignani, Chiara Briani, Giulia Francesca Federici, Gianfranco Delle Fave, Vincenzo David.   

Abstract

PURPOSE: The aim of our study was to evaluate the diagnostic accuracy of gadoxetic acid-enhanced magnetic resonance (MR) imaging both in the detection of hepatocellular carcinoma (HCC) and precancerous lesions and in the assessment of their evolution.
MATERIALS AND METHODS: A retrospective study was undertaken on 56 patients with chronic liver disease and suspected liver lesions. We evaluated the number, size and signal intensity of the nodules on dynamic and hepatobiliary MR images. Follow-up studies were carried out every 3 months. Statistical analysis was performed using the Fisher's exact test.
RESULTS: A total of 120 nodules were identified in 41 patients. Of these, 92/120 nodules (76.6%; mean diameter 18.4 mm) showed the typical HCC vascular pattern: 90/92 nodules appeared hypointense and 2/92 were hyperintense on hepatobiliary phase images. An additional 28/120 hypointense, nonhypervascular nodules (23.3%; mean diameter 11 mm) were detected on hepatobiliary phase images, 15 of which showed hypointensity also on the equilibrium phase images. During the 3- to 12-month follow-up, 14/28 nodules (mean diameter 13.3 mm) developed the typical vascular pattern of HCC.
CONCLUSIONS: Gadoxetic acid-enhanced MR imaging is useful for detecting HCC as well as hypovascular nodules with potential progression to HCC. Lesions measuring more than 10 mm in diameter are at higher risk of developing into HCC (p = 0.0128).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24297598     DOI: 10.1007/s11547-013-0364-x

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  28 in total

1.  Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.

Authors:  Rita Golfieri; Matteo Renzulli; Vincenzo Lucidi; Beniamino Corcioni; Franco Trevisani; Luigi Bolondi
Journal:  Eur Radiol       Date:  2011-02-05       Impact factor: 5.315

2.  Effect of Gd-EOB-DTPA on T2-weighted and diffusion-weighted images for the diagnosis of hepatocellular carcinoma.

Authors:  Kazuhiro Saito; Yoichi Araki; Jinho Park; Ryo Metoki; Hiroaki Katsuyama; Ryota Nishio; Dai Kakizaki; Fuminori Moriyasu; Koichi Tokuuye
Journal:  J Magn Reson Imaging       Date:  2010-07       Impact factor: 4.813

3.  Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.

Authors:  Young Joo Suh; Myeong-Jin Kim; Jin-Young Choi; Young Nyun Park; Mi-Suk Park; Ki Whang Kim
Journal:  AJR Am J Roentgenol       Date:  2011-07       Impact factor: 3.959

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma?

Authors:  Masatoshi Kudo
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

6.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

7.  Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow.

Authors:  Sachiyo Kogita; Yasuharu Imai; Masahiro Okada; Tonsok Kim; Hiromitsu Onishi; Manabu Takamura; Kazuto Fukuda; Takumi Igura; Yoshiyuki Sawai; Osakuni Morimoto; Masatoshi Hori; Hiroaki Nagano; Kenichi Wakasa; Norio Hayashi; Takamichi Murakami
Journal:  Eur Radiol       Date:  2010-05-19       Impact factor: 5.315

8.  Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.

Authors:  Sung Soo Ahn; Myeong-Jin Kim; Joon Seok Lim; Hye-Suk Hong; Yong Eun Chung; Jin-Young Choi
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

9.  Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings.

Authors:  Alexander Huppertz; Thomas Balzer; Anthony Blakeborough; Josy Breuer; Andrea Giovagnoni; Gertraud Heinz-Peer; Michael Laniado; Riccardo M Manfredi; Didier G Mathieu; Dieter Mueller; Peter Reimer; Philip J Robinson; Michael Strotzer; Matthias Taupitz; Thomas J Vogl
Journal:  Radiology       Date:  2004-01       Impact factor: 11.105

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  10 in total

Review 1.  Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI.

Authors:  Stefano Palmucci
Journal:  World J Hepatol       Date:  2014-07-27

Review 2.  Gd-EOB-DTPA-Enhanced Magnetic Resonance Findings of a Giant Inflammatory Hepatocellular Adenoma: a Case Report and Review of the Literature.

Authors:  Marco Di Pietropaolo; Chiara Briani; Emanuela Pilozzi; Francesco Carbonetti; Vincenzo David; Elsa Iannicelli
Journal:  J Gastrointest Cancer       Date:  2015-12

3.  Misleading findings of liver-specific MR contrast agent for radiological diagnosis of cysto-biliary communication in hydatid cysts.

Authors:  Fatma Kulali; Aylin Acar; Aslihan Semiz-Oysu; Tolga Canbak; Kerem Tolan; Yasar Bukte
Journal:  Radiol Med       Date:  2019-02-06       Impact factor: 3.469

Review 4.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

5.  Breakthrough Imaging in Hepatocellular Carcinoma.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

Review 6.  Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

7.  Non-Hypervascular Hypointense Nodules at Gadoxetic Acid MRI: Hepatocellular Carcinoma Risk Assessment with Emphasis on the Role of Diffusion-Weighted Imaging.

Authors:  Chiara Briani; Marco Di Pietropaolo; Massimo Marignani; Francesco Carbonetti; Paola Begini; Vincenzo David; Elsa Iannicelli
Journal:  J Gastrointest Cancer       Date:  2018-09

8.  Risk Factors for Hypervascularization in Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement: A Systematic Review and Meta-analysis.

Authors:  Tae-Hyung Kim; Sungmin Woo; Sangwon Han; Chong Hyun Suh; Richard Kinh Gian Do; Jeong Min Lee
Journal:  Acad Radiol       Date:  2020-09-20       Impact factor: 5.482

Review 9.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

Review 10.  Hepatic tumors: pitfall in diagnostic imaging.

Authors:  Giulia Grazzini; Diletta Cozzi; Federica Flammia; Roberta Grassi; Andrea Agostini; Maria Paola Belfiore; Alessandra Borgheresi; Maria Antonietta Mazzei; Chiara Floridi; Gianpaolo Carrafiello; Andrea Giovagnoni; Silvia Pradella; Vittorio Miele
Journal:  Acta Biomed       Date:  2020-07-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.